Cardiovascular and Renal Effects of GLP-1: Outcomes of Leader trial


Dr David Strain, UK    01 February 2018

with at least 1 CV co-existing condition or 60 years and older having risk factors for CVD. It was observed that liraglutide reduces the risk for CV events, nephropathy events and all-cause mortality, when compared to placebo. Moreover, the effect of liraglutide on the CV outcomes was driven by changes in the incidence of CV death. It was inferred that the beneficial effect of liraglutide on CV effects and death appears to be independent of the lower incidence of severe hypoglycemia, baseline antidiabetic and CV medication use.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.